Kevin Sill, Ph.D.
Chief Executive Officer, Chief Science Officer, President, and Member of the Board of Directors
Kevin Sill, Ph.D., is the Chief Executive Office, Chief Science Officer, President and co-founder of Intezyne. Dr. Sill completed his Ph.D. and M.S. in polymer science and engineering at the University of Massachusetts and holds a B.S. degree in chemistry from the University of Illinois. In November of 2009, Dr. Sill received the inaugural "Young Innovator of the Year" award from R&D Magazine. He is a co-inventor on 27 issued US patents as well as 61 additional international patents and has authored or co-authored 18 peer-reviewed publications in fields spanning polymer chemistry, polymer physics, nanoparticles, and drug delivery applications. Dr. Sill is a registered US Patent Agent. As a principal investigator, he has received over $2.5M in federal research funding. Dr. Sill, a recognized expert in the field of drug delivery, serves on a NIH review panel for Biomaterials, Delivery, and Nanotechnology.
E. Russell McAllister, M.Acc., M.B.A., C.M.B.A.
Chief Financial Officer
Mr. McAllister brings more than 15 years of business development, corporate finance, leadership and strategic advisory experience to the management team at Intezyne. Previously, Mr. McAllister served as the Vice President of Finance for Qu Biologics, a Vancouver, Canada-based clinical-stage immunotherapy company focused on the development of a novel immunomodulator platform technology with applications in both oncology and inflammatory disease, and, prior to that, as the Chief Financial Officer for Lakewood-Amedex, a clinical-stage infectious disease company focused on the development of novel antimicrobial and nRNA platform technologies. Earlier in his career, Mr. McAllister worked in both New York and San Francisco as a Managing Director of Healthcare Investment Banking at H.C. Wainwright (formerly Rodman & Renshaw) and various other healthcare-focused banks, where he engineered the private and public offerings and/or turnarounds of numerous micro- and small-cap biopharmaceutical companies, successfully raising more than $1 billion in capital for his clients in the process. Prior to moving into investment banking, Mr. McAllister worked as a Senior Biopharmaceuticals Equity Research Analyst at Thomas Weisel Partners and Merriman Curhan Ford & Co., where he received 5-star ratings from StarMine. Mr. McAllister began his career as a Senior Accountant in Forensic Services at PriceWaterhouseCoopers. Mr. McAllister holds Masters degrees in both Accounting and Business (Finance) from Northeastern University and dual Bachelor of Arts degrees in Economics and Asian Studies from Rice University. Mr. McAllister was also a fellowship doctoral candidate in Behavioral Finance at the University of Illinois.
Carolyn Paradise, M.D.
Chief Medical Officer
Carolyn Paradise, M.D., serves as Intezyne's Chief Medical Officer. Dr. Paradise is an internist and medical oncologist with over 25 years' experience in the pharmaceutical industry and is currently a consultant for Adalie Biotech Consulting, LLC. Dr. Paradise served as Chief Operating Officer and President at ARMGOPharma, Inc. (2005-2011). Previously, she served as Senior Vice President and Chief Medical Officer of Aton Pharma, Inc. (2002-2004) and oversaw the development of vorinostat which was licensed to Merck and approved as Zolinza, the first HDAC inhibitor to treat cancer. Prior to joining Aton, Dr. Paradise served as an Executive Vice President of Clinical Operations & Regulatory Affairs of Cell Therapeutics, Inc. (1997-2001) where she oversaw the development of Trisenox which was approved by FDA to treat Acute Promyelocytic Leukemia. From 1992 to 1997 she served as Vice President of Clinical Development, Chiron Technologies of Chiron Corporation and obtained FDA approval for Proleukin to treat metastatic melanoma. Dr. Paradise has also held Director positions in the development organizations of Sterling Winthrop Pharmaceutical R&D and Cetus Corporation. In these capacities, she has overseen successful NDA filings of small molecule and biological therapeutics in both the United States and Europe. She has held clinical appointments at Harvard Medical School, Fox Chase Cancer Center and the University of California at San Francisco. From 1994 to 1998, she served as the Assistant clinical professor in the department of medical oncology at UCSF Cancer Center. She completed an oncology/hematology fellowship at the Beth Israel Hospital, Harvard Medical School in Boston, MA. Dr. Paradise holds a B.A. degree from Hunter College and a medical degree from the Free University of Brussels in Belgium.
Suzanne Bakewell, Ph.D.
Vice president, preclinical development
Suzanne Bakewell, Ph.D., serves as Intezyne’s Vice President of Preclinical Development. Dr. Bakewell is a physiologist whose research work has focused on breast cancer, cancer metastasis to bone, and the mechanisms responsible for disease recurrence in cancer patients. Before joining Intezyne Dr. Bakewell was awarded and completed a Susan G. Komen Postdoctoral Fellowship while at the University of Pennsylvania under Dr. Lewis Chodosh. Her doctoral work identified the role of the beta-3 integrin in establishing bone metastases in melanoma cancer and was completed at Washington University in St. Louis. For this research she received the prestigious ASMBR Young Investigator of the Year Award. Dr. Bakewell earned a B.A. in English from the University of Maryland where she graduated magna cum laude and an M.S. in Physiology and Biophysics from the University of Arkansas for Medical Sciences. Dr. Bakewell has also served as reviewer for the journals Nature Biotechnology and Cancer Biology & Therapy.
Intezyne was co-founded by Habib Skaff, Ph.D. and Kevin Sill, Ph.D. in 2004. Dr. Skaff led Intezyne as it’s Chief Executive Officer and Chairman of the Board of Directors over the first eleven years before stepping down in 2016.